Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Transplantation Conditioning | 34 | 2022 | 1635 | 2.090 |
Why?
|
Graft vs Host Disease | 31 | 2024 | 3079 | 1.890 |
Why?
|
Bone Marrow Transplantation | 29 | 2024 | 2729 | 1.870 |
Why?
|
Hematopoietic Stem Cell Transplantation | 41 | 2024 | 5753 | 1.770 |
Why?
|
Cyclophosphamide | 22 | 2023 | 2224 | 1.720 |
Why?
|
Hematologic Neoplasms | 20 | 2019 | 1927 | 1.240 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 9 | 2017 | 266 | 1.070 |
Why?
|
Bone Neoplasms | 9 | 2022 | 2562 | 1.070 |
Why?
|
Chondrosarcoma | 4 | 2021 | 301 | 1.010 |
Why?
|
Tissue Donors | 13 | 2024 | 2393 | 0.990 |
Why?
|
Osteoblastoma | 2 | 2021 | 24 | 0.920 |
Why?
|
Osteoma, Osteoid | 2 | 2021 | 94 | 0.860 |
Why?
|
HLA Antigens | 12 | 2021 | 1338 | 0.650 |
Why?
|
Hematologic Diseases | 3 | 2023 | 500 | 0.630 |
Why?
|
Busulfan | 9 | 2021 | 264 | 0.620 |
Why?
|
Hematopoietic Stem Cell Mobilization | 7 | 2017 | 227 | 0.590 |
Why?
|
Antigens, CD34 | 5 | 2017 | 657 | 0.580 |
Why?
|
Soft Tissue Neoplasms | 3 | 2021 | 1164 | 0.530 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2023 | 316 | 0.520 |
Why?
|
Immunosuppressive Agents | 13 | 2017 | 4207 | 0.520 |
Why?
|
Hospitals, Special | 1 | 2015 | 88 | 0.490 |
Why?
|
Haplotypes | 6 | 2017 | 2728 | 0.460 |
Why?
|
Transplantation, Homologous | 24 | 2020 | 4858 | 0.430 |
Why?
|
Antilymphocyte Serum | 3 | 2021 | 492 | 0.430 |
Why?
|
Vidarabine | 8 | 2021 | 343 | 0.410 |
Why?
|
Histocompatibility Testing | 9 | 2017 | 726 | 0.370 |
Why?
|
Lymphocyte Depletion | 4 | 2012 | 605 | 0.350 |
Why?
|
Lipoma | 1 | 2012 | 294 | 0.350 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2012 | 360 | 0.340 |
Why?
|
Chondroma | 2 | 2021 | 53 | 0.340 |
Why?
|
Fever | 2 | 2014 | 1603 | 0.330 |
Why?
|
Liposarcoma | 1 | 2012 | 288 | 0.330 |
Why?
|
Vidarabine Phosphate | 4 | 2014 | 11 | 0.330 |
Why?
|
Fetal Blood | 4 | 2023 | 1364 | 0.320 |
Why?
|
Achilles Tendon | 2 | 2024 | 181 | 0.310 |
Why?
|
Myeloablative Agonists | 6 | 2016 | 215 | 0.310 |
Why?
|
Bone Marrow | 7 | 2024 | 2919 | 0.310 |
Why?
|
Tendinopathy | 2 | 2024 | 174 | 0.310 |
Why?
|
Guideline Adherence | 2 | 2015 | 2235 | 0.300 |
Why?
|
Tissue and Organ Harvesting | 4 | 2020 | 373 | 0.300 |
Why?
|
Histocompatibility | 4 | 2016 | 327 | 0.290 |
Why?
|
Blood Component Removal | 2 | 2012 | 124 | 0.260 |
Why?
|
Mesenchymal Stem Cell Transplantation | 2 | 2024 | 504 | 0.260 |
Why?
|
Donor Selection | 4 | 2019 | 242 | 0.250 |
Why?
|
Granulocyte Colony-Stimulating Factor | 5 | 2016 | 632 | 0.240 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2021 | 3641 | 0.230 |
Why?
|
Adult | 62 | 2024 | 223055 | 0.230 |
Why?
|
Adolescent | 40 | 2022 | 88794 | 0.210 |
Why?
|
Transplantation, Autologous | 5 | 2024 | 2126 | 0.210 |
Why?
|
Health Care Surveys | 1 | 2010 | 2424 | 0.200 |
Why?
|
Arthroplasty, Replacement, Ankle | 1 | 2022 | 26 | 0.200 |
Why?
|
Humans | 98 | 2024 | 765823 | 0.200 |
Why?
|
Middle Aged | 58 | 2024 | 223016 | 0.190 |
Why?
|
Young Adult | 29 | 2021 | 59849 | 0.190 |
Why?
|
Gene Rearrangement | 3 | 2021 | 1144 | 0.190 |
Why?
|
T-Lymphocytes | 6 | 2017 | 10262 | 0.190 |
Why?
|
Enchondromatosis | 1 | 2021 | 14 | 0.180 |
Why?
|
Aged | 44 | 2024 | 171178 | 0.180 |
Why?
|
Excitatory Amino Acid Agonists | 1 | 2001 | 141 | 0.180 |
Why?
|
N-Methylaspartate | 1 | 2001 | 228 | 0.180 |
Why?
|
Male | 67 | 2024 | 363740 | 0.170 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 297 | 0.170 |
Why?
|
Transplantation Chimera | 4 | 2015 | 609 | 0.170 |
Why?
|
Erythroid Precursor Cells | 1 | 2001 | 211 | 0.170 |
Why?
|
Receptors, Dopamine D1 | 1 | 2001 | 276 | 0.170 |
Why?
|
Chondromatosis, Synovial | 1 | 2019 | 17 | 0.160 |
Why?
|
Immunotherapy, Adoptive | 2 | 2022 | 1511 | 0.160 |
Why?
|
Disease-Free Survival | 11 | 2016 | 6839 | 0.160 |
Why?
|
Pruritus | 1 | 2022 | 377 | 0.160 |
Why?
|
Female | 63 | 2024 | 396050 | 0.150 |
Why?
|
Activin Receptors, Type II | 1 | 2019 | 122 | 0.150 |
Why?
|
Pyramidal Cells | 1 | 2001 | 365 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2022 | 302 | 0.140 |
Why?
|
Haploidy | 2 | 2016 | 128 | 0.140 |
Why?
|
Child | 24 | 2022 | 80509 | 0.140 |
Why?
|
Killer Cells, Natural | 2 | 2017 | 2207 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-fos | 1 | 2019 | 576 | 0.140 |
Why?
|
Hematopoietic Stem Cells | 3 | 2017 | 3406 | 0.140 |
Why?
|
Giant Cell Tumor of Bone | 1 | 2017 | 119 | 0.130 |
Why?
|
Hodgkin Disease | 3 | 2011 | 1383 | 0.130 |
Why?
|
Fibronectins | 1 | 2019 | 720 | 0.120 |
Why?
|
Radioimmunotherapy | 1 | 2015 | 93 | 0.120 |
Why?
|
Living Donors | 2 | 2010 | 646 | 0.120 |
Why?
|
Retrospective Studies | 20 | 2022 | 81505 | 0.120 |
Why?
|
Biopsy, Needle | 1 | 2020 | 1614 | 0.120 |
Why?
|
Cell Separation | 1 | 2001 | 1718 | 0.120 |
Why?
|
Whole-Body Irradiation | 4 | 2021 | 438 | 0.120 |
Why?
|
Erdheim-Chester Disease | 1 | 2014 | 10 | 0.120 |
Why?
|
Osteoarthritis | 1 | 2022 | 1050 | 0.120 |
Why?
|
Dyspnea | 1 | 2022 | 1351 | 0.120 |
Why?
|
Biomarkers, Pharmacological | 2 | 2013 | 161 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2020 | 1315 | 0.110 |
Why?
|
Melphalan | 1 | 2015 | 425 | 0.110 |
Why?
|
Lymphopoiesis | 1 | 2014 | 132 | 0.110 |
Why?
|
Isoantibodies | 1 | 2018 | 681 | 0.110 |
Why?
|
Treatment Outcome | 20 | 2024 | 65223 | 0.110 |
Why?
|
Recurrence | 10 | 2014 | 8506 | 0.110 |
Why?
|
Central Nervous System Neoplasms | 1 | 2022 | 918 | 0.110 |
Why?
|
Graft Survival | 5 | 2015 | 3901 | 0.110 |
Why?
|
Mesenchymal Stem Cells | 1 | 2024 | 1663 | 0.110 |
Why?
|
Area Under Curve | 3 | 2013 | 1639 | 0.110 |
Why?
|
Bacteremia | 1 | 2020 | 988 | 0.110 |
Why?
|
Filgrastim | 4 | 2015 | 130 | 0.100 |
Why?
|
Survival Rate | 8 | 2017 | 12821 | 0.100 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2570 | 0.100 |
Why?
|
Lymphoma | 1 | 2022 | 1895 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1241 | 0.100 |
Why?
|
Foot Diseases | 1 | 2013 | 149 | 0.100 |
Why?
|
Accreditation | 1 | 2015 | 477 | 0.100 |
Why?
|
Pilot Projects | 5 | 2024 | 8725 | 0.100 |
Why?
|
Point-of-Care Systems | 1 | 2001 | 1216 | 0.100 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2019 | 2511 | 0.090 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2412 | 0.090 |
Why?
|
GTP Phosphohydrolases | 1 | 2014 | 523 | 0.090 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2011 | 11855 | 0.090 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9372 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2017 | 614 | 0.090 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2014 | 645 | 0.090 |
Why?
|
Prefrontal Cortex | 1 | 2001 | 2223 | 0.090 |
Why?
|
Synovitis, Pigmented Villonodular | 1 | 2010 | 31 | 0.090 |
Why?
|
Blood Donors | 1 | 2012 | 342 | 0.090 |
Why?
|
Acute Disease | 6 | 2024 | 7237 | 0.090 |
Why?
|
Pain | 5 | 2022 | 5076 | 0.080 |
Why?
|
Graft Rejection | 5 | 2018 | 4501 | 0.080 |
Why?
|
Osteitis | 1 | 2009 | 32 | 0.080 |
Why?
|
Fanconi Anemia | 1 | 2012 | 327 | 0.080 |
Why?
|
Salvage Therapy | 1 | 2016 | 1272 | 0.080 |
Why?
|
Foot | 1 | 2013 | 574 | 0.080 |
Why?
|
Sarcoma | 1 | 2020 | 1800 | 0.080 |
Why?
|
Incidence | 9 | 2023 | 21501 | 0.080 |
Why?
|
Lymphocyte Transfusion | 2 | 2016 | 236 | 0.080 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 2011 | 1374 | 0.080 |
Why?
|
Physician Executives | 1 | 2010 | 140 | 0.080 |
Why?
|
Hospital Bed Capacity | 1 | 2010 | 200 | 0.080 |
Why?
|
Leukemia, Myeloid | 3 | 2014 | 696 | 0.080 |
Why?
|
Mixed Tumor, Malignant | 1 | 2008 | 16 | 0.080 |
Why?
|
Myoepithelioma | 1 | 2008 | 26 | 0.070 |
Why?
|
Liposarcoma, Myxoid | 1 | 2008 | 60 | 0.070 |
Why?
|
Blood Specimen Collection | 1 | 2009 | 238 | 0.070 |
Why?
|
Immunoconjugates | 1 | 2015 | 979 | 0.070 |
Why?
|
Gene Amplification | 1 | 2012 | 1089 | 0.070 |
Why?
|
Fetal Proteins | 1 | 2008 | 99 | 0.070 |
Why?
|
Follow-Up Studies | 7 | 2020 | 39226 | 0.070 |
Why?
|
Killer Cells, Lymphokine-Activated | 1 | 2007 | 42 | 0.070 |
Why?
|
Hemoglobinuria, Paroxysmal | 1 | 2008 | 86 | 0.070 |
Why?
|
Models, Biological | 3 | 2014 | 9441 | 0.070 |
Why?
|
Stem Cell Transplantation | 1 | 2016 | 1601 | 0.070 |
Why?
|
Muscle Neoplasms | 1 | 2008 | 130 | 0.070 |
Why?
|
Histones | 1 | 2017 | 2592 | 0.070 |
Why?
|
Kidney Failure, Chronic | 1 | 2019 | 2498 | 0.070 |
Why?
|
Child, Preschool | 10 | 2022 | 42478 | 0.070 |
Why?
|
Social Class | 1 | 2015 | 2009 | 0.070 |
Why?
|
Chronic Disease | 6 | 2023 | 9355 | 0.060 |
Why?
|
Joint Diseases | 1 | 2010 | 459 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 7 | 2022 | 36542 | 0.060 |
Why?
|
Muscle, Skeletal | 2 | 2013 | 4961 | 0.060 |
Why?
|
Combined Modality Therapy | 4 | 2012 | 8529 | 0.060 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2007 | 304 | 0.060 |
Why?
|
T-Box Domain Proteins | 1 | 2008 | 469 | 0.060 |
Why?
|
Fatigue | 1 | 2012 | 1551 | 0.060 |
Why?
|
Bone Marrow Purging | 2 | 2002 | 108 | 0.060 |
Why?
|
Hemangioma | 1 | 2010 | 724 | 0.060 |
Why?
|
Myelodysplastic Syndromes | 3 | 2016 | 1404 | 0.060 |
Why?
|
Conflict of Interest | 1 | 2010 | 556 | 0.060 |
Why?
|
Chordoma | 1 | 2008 | 343 | 0.060 |
Why?
|
Adoptive Transfer | 1 | 2007 | 827 | 0.060 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 890 | 0.060 |
Why?
|
Kidney Transplantation | 1 | 2019 | 4269 | 0.060 |
Why?
|
Immune Tolerance | 1 | 2012 | 2324 | 0.050 |
Why?
|
Informed Consent | 1 | 2010 | 1009 | 0.050 |
Why?
|
Remission Induction | 4 | 2013 | 2410 | 0.050 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 3110 | 0.050 |
Why?
|
Blood Cell Count | 2 | 2015 | 404 | 0.050 |
Why?
|
Cell Count | 2 | 2019 | 1823 | 0.050 |
Why?
|
Family | 2 | 2011 | 3208 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2021 | 59506 | 0.050 |
Why?
|
United States | 5 | 2023 | 72896 | 0.050 |
Why?
|
Hypoglycemia | 1 | 2009 | 896 | 0.050 |
Why?
|
Knee Joint | 1 | 2010 | 1657 | 0.050 |
Why?
|
2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2001 | 50 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 2017 | 1009 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2017 | 6508 | 0.050 |
Why?
|
State Medicine | 1 | 2022 | 219 | 0.050 |
Why?
|
Hematopoiesis | 2 | 2021 | 2061 | 0.050 |
Why?
|
Arthrodesis | 1 | 2022 | 186 | 0.050 |
Why?
|
Fluorometry | 1 | 2001 | 99 | 0.050 |
Why?
|
Diagnosis, Differential | 4 | 2022 | 12966 | 0.040 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 12520 | 0.040 |
Why?
|
Mutation | 4 | 2020 | 30188 | 0.040 |
Why?
|
Nuclear Family | 1 | 2002 | 311 | 0.040 |
Why?
|
Chimerism | 1 | 2021 | 154 | 0.040 |
Why?
|
Lymphoma, B-Cell | 1 | 2007 | 943 | 0.040 |
Why?
|
Hyperglycemia | 1 | 2009 | 1390 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2007 | 1896 | 0.040 |
Why?
|
Tomography, X-Ray Computed | 3 | 2020 | 20680 | 0.040 |
Why?
|
Ankle | 1 | 2022 | 354 | 0.040 |
Why?
|
Consensus | 2 | 2019 | 3199 | 0.040 |
Why?
|
Oncogene Fusion | 1 | 2019 | 84 | 0.040 |
Why?
|
Switzerland | 1 | 2019 | 322 | 0.040 |
Why?
|
Antigens, CD19 | 1 | 2022 | 442 | 0.040 |
Why?
|
Mycophenolic Acid | 2 | 2013 | 346 | 0.040 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2011 | 4404 | 0.040 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 1 | 2001 | 484 | 0.040 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1375 | 0.040 |
Why?
|
Patch-Clamp Techniques | 1 | 2001 | 918 | 0.040 |
Why?
|
Dopamine Agonists | 1 | 2001 | 346 | 0.040 |
Why?
|
Ankle Joint | 1 | 2022 | 450 | 0.040 |
Why?
|
Hyperplasia | 1 | 2021 | 1146 | 0.040 |
Why?
|
England | 1 | 2019 | 533 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 314 | 0.040 |
Why?
|
Recombinant Proteins | 3 | 2014 | 6489 | 0.040 |
Why?
|
Electrophysiology | 1 | 2001 | 1264 | 0.040 |
Why?
|
Immunohistochemistry | 3 | 2019 | 11033 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2019 | 259 | 0.040 |
Why?
|
London | 1 | 2018 | 233 | 0.040 |
Why?
|
Arthralgia | 1 | 2022 | 457 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 220 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2011 | 4639 | 0.040 |
Why?
|
Postoperative Complications | 3 | 2019 | 15794 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2014 | 7846 | 0.040 |
Why?
|
Calcium Channels | 1 | 2001 | 622 | 0.040 |
Why?
|
Antineoplastic Agents | 4 | 2012 | 13635 | 0.030 |
Why?
|
Animals | 4 | 2022 | 168730 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2023 | 5529 | 0.030 |
Why?
|
Receptors, KIR | 1 | 2016 | 114 | 0.030 |
Why?
|
Lung Neoplasms | 1 | 2020 | 13446 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 983 | 0.030 |
Why?
|
Risk Factors | 7 | 2024 | 74853 | 0.030 |
Why?
|
Cyclosporine | 1 | 1998 | 777 | 0.030 |
Why?
|
Receptors, Tumor Necrosis Factor, Type I | 1 | 2017 | 256 | 0.030 |
Why?
|
Time Factors | 5 | 2017 | 40109 | 0.030 |
Why?
|
Survival Analysis | 4 | 2014 | 10087 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2017 | 305 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 639 | 0.030 |
Why?
|
Extremities | 1 | 2020 | 870 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2017 | 4849 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 642 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2001 | 1295 | 0.030 |
Why?
|
Cause of Death | 2 | 2021 | 3710 | 0.030 |
Why?
|
Spine | 1 | 2021 | 1132 | 0.030 |
Why?
|
Bayes Theorem | 2 | 2014 | 2353 | 0.030 |
Why?
|
Heel | 1 | 2013 | 38 | 0.030 |
Why?
|
Half-Life | 1 | 2014 | 645 | 0.030 |
Why?
|
Injections, Subcutaneous | 1 | 2014 | 682 | 0.030 |
Why?
|
Anesthesia | 2 | 2015 | 1581 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1672 | 0.030 |
Why?
|
Disease Progression | 3 | 2017 | 13613 | 0.030 |
Why?
|
Convalescence | 1 | 2012 | 107 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2014 | 790 | 0.020 |
Why?
|
Decision Trees | 1 | 2014 | 509 | 0.020 |
Why?
|
Prospective Studies | 4 | 2019 | 54798 | 0.020 |
Why?
|
Lymphocytes | 1 | 2019 | 2601 | 0.020 |
Why?
|
Antigens, Surface | 1 | 2015 | 1617 | 0.020 |
Why?
|
Bone and Bones | 1 | 2021 | 2555 | 0.020 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2017 | 954 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9241 | 0.020 |
Why?
|
Pyrazoles | 1 | 2021 | 2031 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2015 | 1865 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2012 | 540 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2001 | 5879 | 0.020 |
Why?
|
Siblings | 1 | 2014 | 828 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2001 | 8105 | 0.020 |
Why?
|
Histocytochemistry | 1 | 2011 | 695 | 0.020 |
Why?
|
Syncope | 1 | 2012 | 431 | 0.020 |
Why?
|
Predictive Value of Tests | 2 | 2019 | 15398 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 3047 | 0.020 |
Why?
|
Europe | 1 | 2015 | 3427 | 0.020 |
Why?
|
Gene Expression | 2 | 2014 | 7581 | 0.020 |
Why?
|
Glutathione Transferase | 1 | 2010 | 562 | 0.020 |
Why?
|
Cytomegalovirus Infections | 1 | 2015 | 836 | 0.020 |
Why?
|
Comparative Effectiveness Research | 1 | 2014 | 713 | 0.020 |
Why?
|
Prognosis | 4 | 2017 | 29915 | 0.020 |
Why?
|
Myeloproliferative Disorders | 1 | 2014 | 615 | 0.020 |
Why?
|
Spermatogonia | 1 | 2008 | 30 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6061 | 0.020 |
Why?
|
International Cooperation | 1 | 2014 | 1432 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 20131 | 0.020 |
Why?
|
Exanthema | 1 | 2012 | 501 | 0.020 |
Why?
|
Hemangioblastoma | 1 | 2008 | 63 | 0.020 |
Why?
|
Leukocytes, Mononuclear | 1 | 2014 | 1856 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 13466 | 0.020 |
Why?
|
Blood Component Transfusion | 1 | 2008 | 138 | 0.020 |
Why?
|
Leukemia | 1 | 2015 | 1523 | 0.020 |
Why?
|
Nonlinear Dynamics | 1 | 2010 | 490 | 0.020 |
Why?
|
Infant | 3 | 2010 | 36375 | 0.020 |
Why?
|
Body Mass Index | 2 | 2015 | 13041 | 0.020 |
Why?
|
Reoperation | 1 | 2017 | 4309 | 0.020 |
Why?
|
Synovial Membrane | 1 | 2010 | 513 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2016 | 15881 | 0.020 |
Why?
|
Body Weight | 1 | 2017 | 4624 | 0.020 |
Why?
|
Leukapheresis | 1 | 2007 | 150 | 0.020 |
Why?
|
Neoplasms | 2 | 2014 | 22349 | 0.020 |
Why?
|
Cell Lineage | 1 | 2015 | 2573 | 0.020 |
Why?
|
Income | 1 | 2015 | 1873 | 0.020 |
Why?
|
Algorithms | 2 | 2011 | 14062 | 0.020 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11205 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5302 | 0.020 |
Why?
|
Multiple Myeloma | 1 | 2003 | 5196 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2010 | 2226 | 0.010 |
Why?
|
Rats | 1 | 2001 | 23707 | 0.010 |
Why?
|
Medicare | 1 | 2023 | 6816 | 0.010 |
Why?
|
Diphosphonates | 1 | 2009 | 625 | 0.010 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2007 | 238 | 0.010 |
Why?
|
Tacrolimus | 1 | 2008 | 754 | 0.010 |
Why?
|
Chromatography, Liquid | 1 | 2008 | 991 | 0.010 |
Why?
|
Virus Activation | 1 | 2006 | 323 | 0.010 |
Why?
|
Gastrointestinal Diseases | 1 | 2012 | 1203 | 0.010 |
Why?
|
Immunotherapy | 1 | 2000 | 4752 | 0.010 |
Why?
|
Receptors, IgG | 1 | 2007 | 559 | 0.010 |
Why?
|
Risk | 1 | 2016 | 9600 | 0.010 |
Why?
|
Drug Monitoring | 1 | 2010 | 960 | 0.010 |
Why?
|
Ambulatory Care Facilities | 1 | 2010 | 937 | 0.010 |
Why?
|
Sex Factors | 1 | 2017 | 10607 | 0.010 |
Why?
|
Cohort Studies | 3 | 2014 | 41643 | 0.010 |
Why?
|
Multivariate Analysis | 2 | 2010 | 12056 | 0.010 |
Why?
|
Proteomics | 1 | 2017 | 3909 | 0.010 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 483 | 0.010 |
Why?
|
Administration, Oral | 1 | 2010 | 4018 | 0.010 |
Why?
|
Amino Acid Substitution | 1 | 2007 | 1739 | 0.010 |
Why?
|
Lung | 1 | 2020 | 10031 | 0.010 |
Why?
|
Testicular Neoplasms | 1 | 2008 | 800 | 0.010 |
Why?
|
Postoperative Care | 1 | 2008 | 1474 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7476 | 0.010 |
Why?
|
Baltimore | 1 | 2001 | 232 | 0.010 |
Why?
|
Health Expenditures | 1 | 2014 | 2386 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2008 | 2194 | 0.010 |
Why?
|
Health Care Costs | 1 | 2014 | 3240 | 0.010 |
Why?
|
Herpesvirus 4, Human | 1 | 2006 | 1078 | 0.010 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2006 | 617 | 0.010 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2009 | 2269 | 0.010 |
Why?
|
Leukocyte Count | 1 | 2002 | 1603 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2014 | 10383 | 0.010 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2000 | 691 | 0.010 |
Why?
|
Antigens, CD | 1 | 2007 | 4020 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2015 | 18289 | 0.010 |
Why?
|
Computer Simulation | 1 | 2010 | 6252 | 0.010 |
Why?
|
Genotype | 1 | 2010 | 13023 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2006 | 6304 | 0.010 |
Why?
|
Blood Glucose | 1 | 2009 | 6422 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 11888 | 0.010 |
Why?
|
Hospitalization | 1 | 2012 | 10803 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2008 | 6545 | 0.010 |
Why?
|
Comorbidity | 1 | 2006 | 10570 | 0.010 |
Why?
|
Obesity | 1 | 2012 | 13078 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16706 | 0.010 |
Why?
|
Neutrophils | 1 | 2002 | 3770 | 0.010 |
Why?
|
Mice | 1 | 2015 | 81788 | 0.000 |
Why?
|
Age Factors | 1 | 2003 | 18380 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2001 | 14745 | 0.000 |
Why?
|